The histamine H,-receptor antagonist SK&F 93479 induced gastric neuroendocrine (carcinoid) ECL-cell tumor formation in 6/34 male and 8/37 female rats treated for 22-24 months at 1,000 mg/kg/day PO. Focal ECL-cell hyperplasia was present in 21/34 males and 15/37 females, with local infiltration through the muscularis mucosae in half these cases. No focal hyperplasias or carcinoids were present after 200 m@g/ day PO treatment. Investigative studies showed evidence for marked and sustained hypergastrinemia increasing on chronic dosing which was capable of restoring gastric acid secretion and pH to near control values. Using morphometric analysis of immunoperoxidase anti-chromogranin A stained sections, a doserelated and time-dependent neuroendocrine ECLcell hyperplasia was correlated with the sustained elevated hypergastrinemia. A 2 l-month mouse oncogenicity study showed no focal neuroendocrine cell hyperplasia or carcinoid tumor induction, but a diffuse neuroendocrine cell hyperplasia and an increase in multifocal glandular hyperplasia of the oxyntic mucosa was observed in mice treated with 1,000 m a g SK&F 93479 PO. The morphological changes observed in both rat and mouse were considered to be secondary to the hypergastrinemia resulting from the pharmacological suppression of gastric acid secretion by SK&F 93479. These changes were also observed to a more marked degree following omeprazole treatment and were only slight following oxmetidine treatment in the rat.
INTRODUC~ION
The development of the histamine H,-receptor antagonist cimetidine represented a major therapeutic advance in the therapy of peptic ulcer disease.
A second generation of more potent, longer-acting H,-antagonists to produce a more sustained blockade of parietal cell stimulation and the development of the irreversible H+/K+ ATPase inhibitor omeprazole demonstrated the ability of such compounds to induce previously unreported gastric enterochromaffin-like (ECL)-cell carcinoid tumors in the rat (1, 5, 13) . Despite the long latent period for tumor development (>80 weeks), it has subsequently been possible to demonstrate early neuroendocrine cell hyperplasia (7, 18) with associated hypergastrinemia (9,18) and activation of histidine decarboxylase * Presented at the Sixth Internitional Symposium of the Society of Toxicologic Pathologists: "Gastrointestinal Toxicologic Pathology," June 113, 1987 in Philadelphia, Pennsylvania. activity (1 8). Although shorter-acting H,-antagonists such as cimetidine, ranitidine, and oxmetidine have not induced ECL-cell focal hyperplasias or carcinoid tumors in 2-year rat oncogenicity studies, a lower degree of hypergastrinemia and diffuse ECLcell hyperplasia have been demonstrated in shorterterm studies (18) . The present report details the short-and long-term gastrin changes associated with SK&F 93479 treatment in rodents, and relates these changes to the ,pharmacological effects of this and other carcinoid-inducing (omeprazole) and non-tumorigenic (oxmetidine) compounds. prepared as the aqueous solution of the -A2 dihydrochloride salt. Omeprazole was synthesized by Byk Gulden Pharmazeutika, Constance, W. Germany, and administered as a suspension of the base in 4% methyl cellulose El5 containing 1.4% w/w propylene glycol as vehicle and adjusted to pH 10 with 1% bicarbonate solution.
Animals. SK&F Wistar SPF bamer-maintained rats were bred by SK&F Research Ltd. and supplied at a 120-200-g weight range for short-term studies. Rats and mice for oncogenicity studies were supplied at 6 weeks of age and maintained in a controlled environment (10-22"C, 40-60% RH, 12 hr light) in a barrier-controlled SPF rodent facility. Animals were fed ad libituitz with PRD diet (Labsure, K+K Greef Ltd., Croydon, UK), except for gastric fistula rats which were fasted overnight prior to gastric acid collection. Tap water was available ad libitum. Gastric fistula preparations in adult female rats of 170-200-g b.w. were made by surgical apposition of the greater curvature of the forestomach to the left lateral abdominal wall and inserting a titanium cannula through into the stomach 3 weeks prior to study.
Normalization of gastric acid secretion was confirmed post-surgically in fistula rats prior to drug treatment. Twelve SK&F 93479 or 6 omeprazole, oxmetidine rats per treatment group were used in parallel with 12 or 6 normal (unfistulated) rats per group, respectively. UFAW animal welfare guidelines were followed in the conduct of all aspects of the experiments. Mice were of outbred Swiss origin and were bred and supplied at 20-35-g (males) or 15-30-g (female) b.w. range by SK&F Research Ltd.
Plastna Gastrin Meastireinent. Rats were restrained or anesthetized With halothane for blood sampling from the tail vessels using a 2 1 G cannula. Samples were collected at specified times post-dosing into tubes containing 120 WIU/ml aprotinin (Sigma Chemical Co., Poole Dorset, UK) and anticoagulant. Plasma was separated by centrifugation within 60 min and samples stored at -20°C until assayed.
A modification of the Gastrin Radioimmunoassay Kit IZ5I (Becton Dickinson Immunodiagnostics, Orangeburg, NY) was employed. Human gastrin G17-I was used as internal standard, as a high level of cross-reactivity with synthetic rat gastric G17-I (8O-86Yo) had been previously established (20) . A 50-pl plasma sample allowed accurate measurements of high gastrin levels, while retaining adequate sensitivity (1 3 pg/ml).
Gastric Pharmacology Studies. Following a 20.5hr overnight fast, the rats were lightly anesthetized with halothane mixed with oxygen (1,000 ml/min) and nitrous oxide (800 ml/min). The silicone rubber bung (Silescol: size E5) closing the fistula cannula was removed and the stomach was then cleared of its contents by rinsing with warmed 0.9% saline solution. A polythene tube, fitting precisely the internal diameter of the gastric cannula, was then inserted into the cannula and a plastic collecting bottle (maximum capacity 2.5 ml) attached to the free end of the tube. The rats were placed in restraining cages and allowed to regain consciousness.
Gastric secretion was collected by gravity drainage. Samples were taken at 45-min intervals, diluted 1 in 10 and then titrated against NaOH (0.1 M) to pH 7.0 using an autoburette (Radiometer Copenhagen). The rate of secretion (total acid outputl45 min) was expressed as the product of volume and total acid concentration.
On days -1,5,12 and 33, secretion was measured 22.5 to 24 hr post-dose (except day -1 when dosing had not commenced). Two samples of gastric secretion were collected. The rats were then fed and dosed 1 hr later. On day 21, gastric secretion was measured from 22.5 to 24 hr post-dose and up to 7.75 hr post the subsequent dose. The fistula was closed between 0 and 2.5 hr post-dose to allow for drug absorption. Fistulae were then closed and the rats returned to their cages and fed.
Gastric Histopathology. At necropsy, the stomach was removed, opened along the greater curvature, any digesta washed off with normal saline, and then pinned out on cork. In selected cases, l-mmwide strips of gastric mucosa were dissected out and fixed in 0.25% glutaraldehyde solution for osmium post-fixation and processing into resins for electron microscopy. Pinned-out stomachs were then photographed where appropriate and then immersionfixed in neutral buffered formalin. Hematoxylin and eosin stained 4-pm sections were prepared from standard longitudinal strips taken from greater curvature (oxyntic mucosa and forestomach), midway to lesser curvature (oxyntic mucosa and forestomach) and lesser curvature (pylorus, antrum, cardia and forestomach) and from macroscopically abnormal areas.
Serial sections were also prepared and mounted on poly-L-lysine-coated slides for immunohistochemistry. PolyclOnal rabbit antisera against the following antigenic specificities were used: anti-chromogranin A (bovine SP-1, Immunonuclear Corp., Stillwater, MN, USA), anti-neuron-specific enolase actions were also performed on selected cases using the gold-enhanced Grimelius and Masson-Fontana methods. Criteria for the classification of neuroendocrine proliferative lesions are given in Results. Morphonzetric Analysis. Quantitation of gastric oxyntic mucosal height and neuroendocrine cell field area (proportional to mass per unit area of mucosa) was performed using a Quantimet 920 (Cambridge Instruments, Cambridge, UK) image analyzer using software developed by SK&F Research Ltd. Using anti-chromogranin A-PAP stained sections of oxyntic mucosa without counterstain, image grey level thresholds were set to detect only neuroendocrine cell cytoplasmic areas within a field of fixed width extending from the line of the muscularis mucosae up to the lumenal mucosa surface, i.e., the mucosal height. Neuroendocrine cell field areas were expressed as absolute area showing positive immunoreactivity @m2) per linear pm of mucosal section. Measurements were made at regular intervals along sections from both greater and mid-lesser curvature where perpendicular gland orientation was obtained (ca. 8-10 fields/stomach) and means calculated for field area and mucosal height. Gastric oxyntic glandular mucosa surface area after pinning out was measured from calibrated photographs and was found to be unchanged pre-vs post-fixation.
RESULTS
Evaluation of hematoxylin and eosin stained sections of the gastric mucosa showed a treatmentrelated focal neuroendocrine cell hyperplasia 0, -= 0.001) and neoplasia ( p < 0.001) (carcinoid tumor formation) in rats treated, for 22-24 months with SK&F 93479-A, at 1,000 mglkglday. No cases were observed in the mid-(200 mg/kg) and low-(40 mg/ kg) dose groups. No such changes were observed in vehicle (water) or unclosed controls (Table I) . ' Focal neuroendocrine cell hyperplasias were usu-ally multifocal, sometimes confluent, areas of replacement of normal gastric glandular elements (parietal and chief cells) by nests of pale-staining ovoid or columnar cells, with small regular nuclei and insignificant mitotic activity. Foci showed poorly demarcated edges with cords of pale neuroendocrine cells breaking up into small clusters at the junction with normal gastric glands ( Fig. 1) . Focal hyperplasia always appeared to originate from the base of the mucosa, never from the proliferative zone at the bottom of the gastric pits. Areas of focal hyperplasia extended upward towards the gastric lumen, replacing normal glandular elements by pale-staining cells in the process (Fig. 2) . In approximately 50% of cases, there was progression to local infiltration of solitary cells, cell clusters or cords through the muscularis mucosae into the submucosa. Despite the apparent invasive behavior at multiple sites, the cytology and mitotic index of infiltrating cells was identical to the neuroendocrine cells in areas of focal hyperplasia (Fig. 3) .
In contrast, benign and malignant neuroendocrine carcinoid tumors were characterized by their solitary or polypoid growth characteristics, with welldemarcated borders locally compressing adjacent gastric glands or areas of focal hyperplasia (Fig. 4) . The cytology showed a more anaplastic appearance, with some nuclear pleiomorphism and an increase in. mitotic index, (Fig. 5 ). Cytoplasmic staining was generally more eosinophilic and cells were arranged in endocrine nests or anaplastic glandular patterns.
Malignancy was diagnosed on the basis of local invasion into the submucosa of nodular masses derived from an intramucosal carcinoid tumor (Figs. 6 and 7). Some microcarcinoid tumor nodules were observed to arise de now from cords of neuroendocrine cells in the submucosa that were derived from focal hyperplasias. In addition, focal clusters of eosinophilic chief cells were observed in some gastric glands or within a focus of neuroendocrine cell hyperplasia. The neuroendocrine ECL-cell identity of the cell type involved was confirmed by argyrophilia on Grimelius staining and positive immunoreactivity for neuron-specific enolase (Fig. 7) , chromogranin A and histidine decarboxylase. Electron microscopy of areas of neuroendocrine cell hyperplasia demonstrated ECGcell characteristics (Fig.  8) , with large lucent vacuoles with very small dense cores.
.Morphometric Analysis of Oxyntic Neuroendocrine Cells'in the Rat. A morphometric analysis of chromogranin A stained sections of oxyntic mucosa was camed out following 35 days oral treatment of female rats with 200 mgkg and 1,000 mg/kg SK&F 93479-A,, 140 mgkg omeprazole, and 900 m a g oxmetidine dihydrochloride. A significant (p -c 0.05) increase in mucosal height was seen only in the case of SK&F 93479-A3 treatment at 1,000 mgkg ( Fig.  9 ). An increase in neuroendocrine cell area was seen following 35 days treatment with SK&F 93479-A, at 1,000 mg/kg (2.30 x control) and 200 mgkg (2.09 x control), with omeprazole at 140 mg/kg (1.83 x control, Fig. 10) and with oxmetidine at 900 mg/kg (1.52 x control, Fig. 11) . Short-term exposure was therefore detectable after 35 days treatment with all antisecretory agents at all doses tested. -Gastric mucosa from rat treated with SK&F 93479-A, (1,000 mg/kg) for 2 years. Chromogranin-immunoreactivity of well-demarcated spherical intramucos-a1 carcinoid tumors is less than adjacent diffusely and focally hyperplastic neuroendocrine cells, but still positive. CgA-PAP. x 60.
Morphometric analysis of gastric mucosa from rats treated for 22-24 months with SK&F 93479-A, in the oncogenicity study was carried out in regions of oxyntic mucosa not involved by focal hyperplasia or neoplasia of neuroendocrine cells. Forty mg/kg and 200 mg/kg dose groups showed no significant difference from control groups, but the 1,000 mg/kg dose group showed a marked and significant (p < 0.001) increase in both mucosal height and neuroendocrine cell field area. It should be noted that control rats showed a spontaneous, age-related increase in neuroendocrine cell field area, with a greater than 3-fold increase compared to young rats.
Uncounterstained chromogranin A-PAP stained sections of stomach clearly showed the diffuse neuroendocrine cell hyperplasia with increased number and size of neuroendocnne cells. These sometimes form small clusters, unlike the dispersed control pat-tern. Focal hyperplasia and infiltrating cells were also strongly immunoreactive ( Fig. 12 ) for chromogranin A, whereas carcinoid tumors showed somewhat weaker, but uniformly positive, immunoreactivity ( Fig. 13) .
Plasma Gastrin Response and Gastric Acid Secrefion and pH. Plasma gastrin was measured pretest and on days 5, 12,21 (not for SK&F 93479 in unfistulated rats) and 33 for all compounds around the time of peak pharmacological effect (6 hr, unfistulated rats only), and at 24 hr post-dosing. Plasma gastrin profiles for unfistulated animals are present on the same scale for SK&F 93479 (Fig. 14) , omeprazole (Fig. 1 3 , and oxmetidine (Fig. 16) , respectively. Very marked and significant (p < 0.001) elevation in 6-hr gastrin values was seen for all 3 compounds, but large differences existed in the magnitude of the peak values from ca. 250 pgml for oxmetidine, 400-500 pg/ml for SK&F 93479, and 600-1,100 pg/ml for omeprazole. In the latter case, there was a progressive rise in 6-and 24-hr gastrin values through to day 33.
Twenty-four-hr gastrin values were in the normal range for oxmetidine and the non-carcinoid-inducing dose (200 mg/kg) of SK&F 93479. However, carcinoid-inducing doses of both SK&F 93479 and omeprazole showed sustained hypergastrinemia throughout the 24-hr dosing interval, and in the case of omeprazole, 24-hr gastrin values were only slightly lower than 6-hr values. Measurement of gastric acid output and pH (1: 10 diluted sample) was made after 21 days dosing with each compound-over a 90-min pre-dose period. Fistulae were then closed for 2 hr to permit compound absorption, and gastric secretion was again collected from 2.5 to 7.75 hr post-dosing.
Despite the very high toxicological doses used, which produce marked sustained antisecretory activity in single dose pharmacology experiments (SK&F 93479 (1,000 mg/kg), 639' 0 inhibition at 24 hr; omeprazole (140 m&), 75% inhibition at 24 hr; oxmetidine (900 mg/kg), 33% inhibition at 24 hr), on chronic dosing the reduction in acid output and the rise in pH post-dosing was much less than after single dose administration, although it was still statistically signiocant for all compounds (p C 0.05). Only omeprazole (140 mg/kg) resulted in near complete abolition of gastric acid secretion and markedly elevated gastric pH up to 7.75 hr post-dosing . Remarkably, gastric acid output and gastric pH returned to control values at 24 hr postdosing. In the case of omeprazole, there was a small but significant (p c 0.05) increase in acid output and reduction in pH compared to controls at 24 hr post-dosing.
Moilse Oncogenicity Study. High dose (1,000 me/ kg PO) SK&F 93479-A, treated and control mice TOXICOLOGIC PATHOLOGY dosed for 21 months were subjected to a histological examination of the gastric mucosa and a morphometric analysis of neuroendocrine cell numbers. No focal neuroendocrine cell hyperplasia or carcinoid tumors were present in any of the mouse stomachs examined. There was, however, an exacerbation of the multifocal epithelial hyperplasia seen spontaneously in aged SK&F Swiss mice (Table 11) . Two cases, both in treated mice, showed herniation of hyperplastic oxyntic glands through the muscularis mucosae ( Figs. 21 and 22) . Although relatively minor compared to changes observed with 1,000 mgl kg in SK&F 93479-A3 treated rats at 2 years, an increase in mucosal height and neuroendocrine cell field area was present on morphometric analysis on 21-month-old mouse stomachs (Fig. 23) .
DISCUSSION
The advent of newly reported drug-induced ECLcell carcinoid tumors of the rat oxyntic mucosa following administration of newer antisecretory agents (1, 5, 13) provided an immediate indication of this change being a pharmacological class effect. None of the agents involved (SKBF 93479, loxtidine, omeprazole) was considered to be a genotoxic carcinogen on the basis of short-term assays.
Equally, standard genotoxic gastric carcinogens, e.g, N-methyl-N-nitro-N-nitrosoguanidine (MNNG), and the H,-receptor antagonist tiotidine, typically produced exocrine adenocarcinomas of the antral mucosa (15, 16) , with the exception of 1 report in which gastric carcinoids were reported (19). It is known, however, that high doses of MNNG can be directly cytotoxic, leading to an atrophic gastritis with hypergastrinemia (10). The overwhelming body of experience ofgenotoxic gastric carcinogenesis with MNNG is that it is a quite separate process from that associated with antisecretory agents in the rat. Certain studies of MNNG carcinogenesis have examined the possible promoting role of gastrin in exocrine adenocarcinoma development. Results have been inconclusive overall (20, 23) . In cases where rats have been exposed to MNNG plus gastrin, as opposed to MNNG alone, some carcinoid tumors have been described. However, the absence of a gastrin-alone control group does not eliminate the possibility that these carcinoids resulted from gastrin exposure alone.
Gastrin infusion studies in the rat have demonstrated a trophic action of this hormone on E C L cell populations. Proposals that ECL-cell hyperplasia is secondary to a general trophic action ofgastrin on the pluripotential stem cells in the proliferative zone (12) can be discounted, since an ECL-cell hyperplasia can be seen without a general trophic effect (1,000 mg/kg/day PO).
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on the mucosa (i.e,, no increase in mucosal height), the ECL-cell hyperplasia extends upwards from the base of the mucosa towards the proliferative zone, not vice versa, and thymidine labelling has demonstrated stimulation of mitotic activity in differentiated ECL cells (21) . It is therefore concluded that the gastrin-related oxyntic ECL proliferative response to treatment with antisecretory agents represents an entirely separate process from the stages in gastric carcinogenesis leading to (exocrine) adenocarcinoma generation. The short-term experimental studies reported above have demonstrated a good correlation between compoung rank order potency and duration of action and the consequent pharmacologically-induced hypergastrinemia and neuroendocrine cell hyperplasia. Hypergastrinemia returning to normal range at 24 hr post-dose and to a low degree of neuroendocrine cell hyperplasia appears to be below the threshold required for the ultimate production of focal ECL-cell hyperplasias and carcinoid neoplasia in 2-year rat oncogenicity studies, e.g., after oxmetidine or 'low' dose SK&F 93479 or cimetidine (8) treatment. Conversely, potent long-acting phar- macological effects of omeprazole or of high doses of SK&F 93479 resulting in marked sustained hypergastrinemia and greater degrees of neuroendocrine cell hyperplasia in the short term were predictive for ultimate progression to ECLcell carcinoid tumors by 2 years. The long apparent latent period may reflect a multistage non-genotoxic mechanism in this progression. The chronic dosing pharmacology results were somewhat unexpected on the basis of the very large multiple of the single dose EDso administered (=5 pmoVkg for SK&F 93479 PO).
In the case of SK&F 93479, chronic dosing resulted in some homeostatic process restoring gastric acid output and pH to near normal basal (fasting) secretion profiles. This surmountable inhibition may represent the agonist effects of the hypergastrinemia largely overwhelming the H,-receptor antagonism by restoring acid secretion to basal (but not stimulated) levels. The gastric milieu never attained the achlorhydric conditions permissive for bacterial overgrowth and nitrosamine generation.
Marked inhibition of acid output and achlorhydria were sustained after chronic omeprazole treatment for part of the day only. A requirement for "unsurmountable" antagonism (3) would therefore seem less relevant for carcinoid tumor induction than the ability to sustain a marked hypergastrine-mia. Indeed, multiple or continuous high-level dosing regimens or a non-carcinoid inducing H,-receptor antagonist (ranitidine) can reproduce the early changes induced by omeprazole (1 8) .
The relevance of these toxicological changes in the rat to human clinical usage has been the subject of much debate. The mouse and the dog have exhibited some non-neoplastic changes following treatment with these potent, long-acting antisecretory agents, but only loxtidine (14) and ICI 162,846 (1 7) have produced ECL-cell carcinoids in a second species, the mouse. No ECL-cell hyperplasia or neoplasias in man have been reported following clinical use of therapeutic doses of existing or new-generation antisecretory agents. Hypergastrinemia in patients has been reported, but is of very low magnitude (2-3 x control) and is rapidly reversible, even after omeprazole treatment. ECL cells are both numerically and functionally more significant in the rat than in dog or man, where mast cells serve as the source of intramucosal histamine generation.
It is only in conditions of severe and prolonged hypergastrinemia that gastric ECL-cell carcinoids are predisposed to, i.e., chronic atrophic gastritis (Type A CAG) of the fundic mucosa (pernicious anemia) and Zollinger-Ellison syndrome (2, 4, 6, 11) . In the former, conditions of achlorhydria and intestinal metaplasia (predisposing also to exocrine carcinomas) exist, whereas in the latter, functional gastrinoma produces hypersecretion of gastric acid. The common feature of these risk factors for ECLcell gastric carcinoids is marked and sustained hypergastrinemia. More detailed study of CAG patients has shown a good correlation between degree of hypergastrinemia and the argyrophil (neuroendocrine) cell diffuse hyperplasia focal hyperplasia carcinoid tumor sequence (4). The degree of hyper- gastrinemia attained during therapy of peptic ulcer disease with even highly potent agents such as omeprazole falls below the lowest of these risk categories.
The pathophysiology of gastrin regulation following treatment with antisecretory agents therefore appears to be more labile (hyper-reactive) in the rat than in man. The sequalae of this exaggerated endocrine feedback response therefore may exhibit lower thresholds in the rat than for man in this nongenotoxic pharmacological class effect on the gastric mucosa.
